Posts
Est. 2026 · Pennsylvania
The Border
Liter
One in Ten Liters · The Architecture at Its Outer Edge
More than fifty plasma collection centers sit within fifty miles of the US–Mexico border. They are there because of the border — not in spite of it. Mexican nationals cross with tourist visas to sell plasma twice a week. The compensation is modest in dollars. In pesos, it is a living. One in every ten liters of American source plasma traces to this crossing.
The domestic plasma siting model examined in Post III exploits the poverty gradient within American cities — placing collection infrastructure where economic need is concentrated. The border model is the same architecture amplified by a factor that no domestic poverty gradient can match: the wage differential between the United States and Mexico.
In 2025, the US federal minimum wage stands at $7.25 per hour. Mexico's daily minimum wage, by contrast, is approximately 248 pesos — roughly $13 to $14 USD at current exchange rates, for a full workday. A single plasma donation session paying $80 USD represents the equivalent of five to six full days of Mexican minimum wage labor. Two sessions per week, the FDA maximum, yields a monthly plasma income that in purchasing power terms substantially exceeds many formal employment options available in border communities on the Mexican side.
The industry did not create this differential. But it built infrastructure to harvest it. The fifty-plus collection centers within fifty miles of the US–Mexico border are not serving American communities that happen to be near the border. They are positioned to intercept the cross-border flow of donors for whom the US–Mexico wage gap transforms a modest dollar payment into a significant economic event.
The mechanism by which Mexican nationals access US collection centers is the B-1/B-2 visa — or, more commonly for border residents, the DSP-150 Border Crossing Card, a biometric document that functions as a combined B-1/B-2 authorization for short-duration entries. These documents are issued for tourism, business, and medical treatment. They explicitly prohibit "work" in the United States — defined as labor performed for hire on behalf of a US employer.
For decades, compensated plasma donation existed in the gap between those categories. It was not tourism. It was not business travel in any conventional sense. It was not the kind of medical treatment the visa category was designed to accommodate. But it was also not, in the industry's framing, work — it was "donation," "compensation for time," a voluntary act with incidental payment. The same terminology that insulates the domestic model from commodification critique also, quite usefully, kept the cross-border transaction out of the "work for hire" definition that would have made it a visa violation.
The word "donation" does not merely insulate the industry from ethical critique. At the border, it insulates the transaction from immigration law. The terminology earns its keep twice.
The gray zone was formalized in 2021. US Customs and Border Protection shifted its enforcement position, classifying compensated plasma donation as labor for hire — work, in the statutory sense — and therefore prohibited under B-1/B-2 authorization. Donors began to be turned away at ports of entry. Centers near the border reported significant volume drops. The supply impact was measurable: cross-border donors contributed an estimated ten percent of US source plasma, and disrupting that flow created shortfalls that rippled through the processing pipeline.
The industry's response was immediate and well-resourced. Grifols and CSL, the two companies with heaviest concentration of border-area collection infrastructure, joined a legal challenge arguing that compensated plasma donation is not labor for hire within the meaning of immigration law. In 2022, a federal court issued a preliminary injunction restoring cross-border donor access pending resolution of the underlying legal question.
As of 2025 and 2026, the injunction remains in effect. The underlying question — whether selling plasma for cash, twice a week, at a facility built specifically to attract you across an international border, constitutes work — remains unresolved in federal court. The practice continues. The supply continues. The legal foundation on which it rests is a temporary judicial order, not settled law.
The concentration of collection infrastructure along the Texas border is not uniform. It clusters at the major crossing points — the cities where pedestrian and vehicle traffic is highest, where the crossing infrastructure is most developed, and where the population on the Mexican side has the greatest density of individuals for whom the economic calculation makes sense.
The border model is the domestic model at higher resolution. The siting methodology — locate collection infrastructure where economic need is most acute, where the compensation offered will be most motivating relative to local alternatives — is identical. The border simply provides a steeper gradient than any domestic poverty census tract can offer. The international wage differential is not a new principle. It is the same principle at national scale.
It also reveals something about the industry's relationship to legal ambiguity. The domestic model operates within clear regulatory permission — the FDA explicitly permits compensated source plasma collection. The border model has operated, for decades, in a space where the legal basis was untested and then contested. When CBP moved to enforce, the industry litigated. When the court issued an injunction, the industry collected. The border liter is not merely a supply line. It is a demonstration of how much legal risk the industry will absorb to protect a revenue-critical supply source.
The border model completes the arbitrage structure of the blood economy. Domestic model: leverages national poverty gradient (poor census tracts within US cities). Border model: leverages international wage differential (Mexican minimum wage vs. US plasma compensation). The principle is identical. The scale is different. The domestic model extracts from American poverty. The border model extracts from the gap between two countries' economic conditions — a gap the collection center did not create but was built specifically to exploit. One in every ten liters of American plasma crosses an international border before it enters the supply chain. That liter is not incidental. It is load-bearing.
The cross-border donor is a specific human being navigating a specific economic reality. They are not an abstraction. For many, the twice-weekly crossing to a collection center in Laredo or El Paso is a rational economic decision — one of the better options available given their circumstances. The plasma income may fund a child's school fees, cover a rent payment, or provide the margin of financial stability that their local formal economy cannot.
This is not an argument against them. It is an argument about the system that depends on them. A supply chain that requires human beings to cross an international border twice a week, sell plasma to sustain a global medicine market, and do so in a legal gray zone that a federal injunction is currently maintaining — that supply chain is not stable. It is not ethical in any robust sense. And it is not, in the industry's own framing as a safe and voluntary system, as clean as the language suggests.
The industry defends the border model on the same grounds it defends the domestic one: voluntary participation, rigorous screening, life-saving products, patient access. These are not false claims. The screening is real. The medicines are life-saving. The participation is, in the legal sense, voluntary. But the architecture underneath those claims — built on the largest wage differential in the Western Hemisphere, sustained by judicial injunction, operated by two companies that control most of the collection infrastructure — is not the portrait of voluntary altruism the terminology implies.
Next · Post V · The Caucus and the Standard — The PPTA–FDA relationship, who funds the safety studies, the Congressional Plasma Caucus, and how regulatory capture is maintained at the institutional level.
No comments:
Post a Comment